| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-107 |
Sentence |
denotes |
Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer. |
| TextSentencer_T2 |
108-205 |
Sentence |
denotes |
Cyclin E is a well-characterized cell cycle regulator and an amplified oncogene in breast cancer. |
| TextSentencer_T3 |
206-283 |
Sentence |
denotes |
Over-expression of cyclin E has generally been associated with poor survival. |
| TextSentencer_T4 |
284-396 |
Sentence |
denotes |
Recent studies have shown an interaction between HER-2 (ERBB2) and cyclin E, but the exact mechanism is unknown. |
| TextSentencer_T5 |
397-485 |
Sentence |
denotes |
Interestingly, cyclin E over-expression has been associated with trastuzumab resistance. |
| TextSentencer_T6 |
486-656 |
Sentence |
denotes |
We studied cyclin E over-expression, CCNE1 amplification, and relapse-free survival in HER-2-positive primary breast cancers treated with and without trastuzumab therapy. |
| TextSentencer_T7 |
657-760 |
Sentence |
denotes |
Formalin-fixed paraffin-embedded tissue samples from 202 HER-2-positive breast carcinomas were studied. |
| TextSentencer_T8 |
761-865 |
Sentence |
denotes |
Expression levels of cyclin E and proliferation marker Ki-67 were determined using immunohistochemistry. |
| TextSentencer_T9 |
866-1024 |
Sentence |
denotes |
Chromogenic in situ hybridization (CISH) with a gene-specific bacterial artificial chromosome (BAC) probe was used to analyze presence of CCNE1 amplification. |
| TextSentencer_T10 |
1025-1118 |
Sentence |
denotes |
Majority of HER-2-positive breast carcinomas exhibited nuclear staining for cyclin E protein. |
| TextSentencer_T11 |
1119-1180 |
Sentence |
denotes |
Cyclin E was highly expressed (≥50 % cells) in 37 % of cases. |
| TextSentencer_T12 |
1181-1256 |
Sentence |
denotes |
Incidence of CCNE1 amplification (≥6 gene copies/cell or clusters) was 8 %. |
| TextSentencer_T13 |
1257-1378 |
Sentence |
denotes |
Cyclin E amplification and over-expression were strongly associated with each other, grade, hormone receptors, and Ki-67. |
| TextSentencer_T14 |
1379-1557 |
Sentence |
denotes |
Neither high cyclin E expression nor CCNE1 amplification was associated with relapse-free survival (RFS) irrespective of short-term (9-week regimen) adjuvant trastuzumab therapy. |
| TextSentencer_T15 |
1558-1668 |
Sentence |
denotes |
These results confirm cyclin E and HER-2 gene co-amplification in a fraction of HER-2-positive breast cancers. |
| TextSentencer_T16 |
1669-1844 |
Sentence |
denotes |
Cyclin E is frequently over-expressed but appears to have limited value as a prognostic or predictive factor in HER-2-positive breast cancer regardless of trastuzumab therapy. |
| T1 |
0-107 |
Sentence |
denotes |
Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer. |
| T2 |
108-205 |
Sentence |
denotes |
Cyclin E is a well-characterized cell cycle regulator and an amplified oncogene in breast cancer. |
| T3 |
206-283 |
Sentence |
denotes |
Over-expression of cyclin E has generally been associated with poor survival. |
| T4 |
284-396 |
Sentence |
denotes |
Recent studies have shown an interaction between HER-2 (ERBB2) and cyclin E, but the exact mechanism is unknown. |
| T5 |
397-485 |
Sentence |
denotes |
Interestingly, cyclin E over-expression has been associated with trastuzumab resistance. |
| T6 |
486-656 |
Sentence |
denotes |
We studied cyclin E over-expression, CCNE1 amplification, and relapse-free survival in HER-2-positive primary breast cancers treated with and without trastuzumab therapy. |
| T7 |
657-760 |
Sentence |
denotes |
Formalin-fixed paraffin-embedded tissue samples from 202 HER-2-positive breast carcinomas were studied. |
| T8 |
761-865 |
Sentence |
denotes |
Expression levels of cyclin E and proliferation marker Ki-67 were determined using immunohistochemistry. |
| T9 |
866-1024 |
Sentence |
denotes |
Chromogenic in situ hybridization (CISH) with a gene-specific bacterial artificial chromosome (BAC) probe was used to analyze presence of CCNE1 amplification. |
| T10 |
1025-1118 |
Sentence |
denotes |
Majority of HER-2-positive breast carcinomas exhibited nuclear staining for cyclin E protein. |
| T11 |
1119-1180 |
Sentence |
denotes |
Cyclin E was highly expressed (≥50 % cells) in 37 % of cases. |
| T12 |
1181-1256 |
Sentence |
denotes |
Incidence of CCNE1 amplification (≥6 gene copies/cell or clusters) was 8 %. |
| T13 |
1257-1378 |
Sentence |
denotes |
Cyclin E amplification and over-expression were strongly associated with each other, grade, hormone receptors, and Ki-67. |
| T14 |
1379-1557 |
Sentence |
denotes |
Neither high cyclin E expression nor CCNE1 amplification was associated with relapse-free survival (RFS) irrespective of short-term (9-week regimen) adjuvant trastuzumab therapy. |
| T15 |
1558-1668 |
Sentence |
denotes |
These results confirm cyclin E and HER-2 gene co-amplification in a fraction of HER-2-positive breast cancers. |
| T16 |
1669-1844 |
Sentence |
denotes |
Cyclin E is frequently over-expressed but appears to have limited value as a prognostic or predictive factor in HER-2-positive breast cancer regardless of trastuzumab therapy. |